目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Psoriasis Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Psoriasis Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining Power of the Suppliers
3.4.1.2. Bargaining Power of the Buyers
3.4.1.3. Threats of Substitution
3.4.1.4. Threats From New Entrants
3.4.1.5. Competitive Rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape

Chapter 4. Psoriasis Drugs Market: Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Psoriasis Drugs Market: Class Movement Analysis, USD Million, 2023 & 2030
4.3. Tumor Necrosis Factor Inhibitors
4.3.1. Tumor Necrosis Factor Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Interleukin Inhibitors
4.4.1. Interleukin Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Vitamin D Analogues
4.5.1. Vitamin D Analogues Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Corticosteriods
4.6.1. Corticosteriods Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Psoriasis Drugs Market: Treatment Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Psoriasis Drugs Market: Treatment Movement Analysis, USD Million, 2023 & 2030
5.3. Topicals
5.3.1. Topicals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Systemic
5.4.1. Systemic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biologics
5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Psoriasis Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Psoriasis Drugs Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
6.3. Oral
6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Topical
6.5.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Psoriasis Drugs Market: Distribution Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Psoriasis Drugs Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
7.3. Hospital Pharmacies
7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail Pharmacies
7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Psoriasis Drugs Market: Regional Estimates & Trend Analysis
8.1. Psoriasis Drugs Market Share, By Region, 2023 & 2030, USD Million
8.2. North America
8.2.1. North America Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Sweden Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Norway Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Japan Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. China Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. Australia
8.4.5.1. Australia Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. South Korea Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. UAE Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Kuwait Psoriasis Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. AbbVie Inc.
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/Strategic Initiatives
9.4.2. Amgen Inc.
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/Strategic Initiatives
9.4.3. Johnson & Johnson Services, Inc.
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/Strategic Initiatives
9.4.4. Novartis AG
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/Strategic Initiatives
9.4.5. Eli Lilly and Company
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/Strategic Initiatives
9.4.6. AstraZeneca
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/Strategic Initiatives
9.4.7. Celgene Corporation
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/Strategic Initiatives
9.4.8. UCB S.A.
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/Strategic Initiatives
9.4.9. Merck
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/Strategic Initiatives
9.4.10. Boehringer Ingelheim International GmbH
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/Strategic Initiatives